A tumor marker is a substance present in the blood, urine, or tissue of the body & referred to as proteins made by the healthy & cancer cells. Tumor markers, also known as biomarkers, are any physical, cellular, chemical, or molecular change that can be noted or studied. These substances are used principally for understanding the effects of treatment, occurrence, progress, & disease risk by examining any modification in their usual amount.
The Saudi Arabia Tumor Marker Market is projected to grow at a substantial CAGR during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the growing focus of the Saudi government on enhancing the healthcare infrastructure, coupled with its support through massive investments, initiatives, and norms for the development of tumor markers across the country.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Region Covered||North, West, South, East, Central|
|Key Companies Profiled||Fujirebio, Randox, Bio-Rad, Cepheid, Roche, MP Biomedicals, DiaSorin, Leica Biosystems, Biomerieux|
|Unit Denominations||USD Million/Billion|
Besides, with an accelerating number of cancer patients and individuals seeking personalized medicines, the demand for tumor markers is surging swiftly & generating growth opportunities for the leading players to introduce treatments to the people, which, in turn, would further boost the market over the forecast years. Moreover, several pharmaceutical companies inclining toward research & developments on biomarkers to diagnose & treat cancer are also projected to augment the overall market growth through 2027.
Impact of Covid-19 on the Saudi Arabia Tumor Marker Market
The advent of Covid-19 in 2020 had a decelerating effect on most industries across Saudi Arabia, yet the Tumor Marker Market witnessed minimal impacts. Owing to the severity of the pandemic, the government had to suspend different business operations in the country and impose stringent movement restrictions & lockdowns to curb the spread of this dreadful disease.
Since the pandemic had an exponential pressure on the healthcare sector, the government & healthcare professionals prioritized addressing Covid-19 cases and put a temporary hold on other patients whose conditions were not severe and could sustain on medicines. It, in turn, introduced challenges for the leading players in tumor marker development since public gatherings & institutions were suspended. However, since the healthcare sector & medical requirements of the people were categorized as priorities, the demand for tumor markers remained prevalent amidst the crisis.